Many companies developed blood tests for cancer, but none of them have FDA approval so far.
The U.S. is preparing to launch trials of blood tests that can improve the detection of multiple kinds of cancer, according to a report.
Solarseven/iStock.
The majority of the multi-cancer early detection tests (MCEDs) function by searching for tumor cell remnants that explode after being attacked by the immune system. Debris from dead tumors can be found in the bloodstream, where it can be identified as a cancer warning before symptoms appear. And if imaging confirms the result, a biopsy follows the process.
Comments are closed.